If you haven’t heard of Coriolus Versicolor then do not worry because not many people have. Just Google it and see what it does. then you may start to realise that you are reading about the chance to change your financial future.

Coriolus isnt just big….its a game changer, life changer….what ever you want to call it. And you have the chance to get in on the ground floor of a business that is set to change lives.

inForce by inLife LLC is a propietary extraction of Coriolus Versicolor PSK & PSP. its immune system boosting qualities are out there in the 400+ independent studies, clinical trials and articles. its ant cancer properties and anti tumour effects can be read and studied.

inForce is set to change your families health and if you want to get paid for telling the people around you about this incredible mushroom then you have a chance to get involved in the biggest network marketing explosion the industry has ever seen.

This is probably one of the first posts ever written about the opportunity for Network marketing and Coriolus Versicolor.

So go away and do the research and also click on the link to view information about inLife and its other products.

View information about inForce by inLife – Click here

Go to Google search

Numerous clinical trials have been carried out over the years with PSK derived from Trametes versicolor (Coriolus versicolor, Poyporous Versicolor, Turkey tail, Yun Zhi) and are briefly summarised below:

PSK:

There have been several decades of successful clinical trials using PSK to treat head and neck, upper GI, colo-rectal and lung cancers with some reported success in treating breast cancer as well.  Clinical trials with PSK have recently been extensively reviewed by Kidd (2000) and will be briefly summarised here.  Almost exclusively, clinical trials have been carried out in Japan.

PSK and gastric cancer:

PSK has been used as a form of immunotherapy for more gastric cancer patients than any other cancer type.  In early 1970s Kaibara’s group began trialing PSK with their existing chemotherapy regimens for stage IV disease (Kaibara et al., 1976).  After surgical resection (partial or full gastrectomies), PSK at 3g per day was added to a chemotherapy regimen of Mitomycin C and 5-fluorouracil (5-FU) (n=66). When compared with a historical control group, the 2 year survival rate was more than double, a finding that was later confirmed by Fujimoto et al. (1979) in a larger prospective study (n= 230).  Further studies by Hattori et al. (1979) (n=110) and Kodama et al. (1982) (n =450) suggested that PSK gave some protection against the immunosuppression that normally is associated with surgery and long-term chemotherapy.

One of the few double-blind randomised controlled trials (n=144) examining the role of single agent PSK found a significant increase in disease-free and overall survival.  PSK had significant effects on these patients immune systems as measured by increased delayed-type hypersensitivity on skin tests and enhanced chemotactic migration of neutrophils (Kondo and Torisu, 1985). All these studies suggest that individuals with very low immunity are less likely to benefit from PSK therapy than individuals with a reasonably competent immune system.  Other non- randomised trials in Japan have supported these findings (Mitomi and Ogoshi, 1986; Niimoto et al., 1988; Maehara et al., 1990; Nakazato et al., 1994).  Tsujitani et al. (1992) had previously observed that dendritic cells could infiltrate gastric cancers in some patients and biopsy examination correlated this dendritic infiltration of their tumours with an increase in disease-free and overall survival post-surgery.  It was concluded that patients with gastric cancer with limited dendritic cell infiltration prior to surgery when given PSK immunotherapy were more likely to have significant response.  The most recent phase III 2 arm trial of PSK in the treatment of gastric cancer carried out by the “Study Group of Immunochemotherapy with PSK for Gastric Cancer of Japan” showed that combining PSK with conventional chemotherapy significantly improved disease-free and overall survival (Nakazato et al., 1994).

PSK and other cancers

In a non-controlled, retrospective analysis of combined radiation, chemotherapy and immunotherapy (using PSK or OK-32, another immuno- potentiator) with 133 patients with oesophageal cancer, there were improvements in one-year and two-year survival (Okudaira et al., 1982).  In another more recent study PSK improved overall survival in oesophageal cancer in patients with levels of pre-operative high α1-anti-chymotrypsin or sialic acid (Ogoshi et al., 1995).  In a small scale trial in Taiwan for nasopharngeal carcinoma PSK adjunct therapy had a small but significant impact on five-year survival (Go and Chung, 1989).

In a study of 185 patients with epidermoid carcinoma, adenocarcinoma or large-cell carcinoma (≤ IIIb) given PSK as an immune system potentiator following radiotherapy, almost four times more patients who were treated with PSK had significant improvements in disease-free survival than those not given PSK (Hayakawa et al., 1993).  PSK was clinically significant with more advanced patients with Stage III disease than Stage I and II patients.  PSK had greater activity for older patients (> 70 years) and patients with small primary tumours. Early studies with breast cancer patients seemed to imply that long-term PSK immunotherapy in conjunction with chemotherapy could have beneficial results (Suginachi et al., 1984).  In a later much larger trial (914 patients) in-depth analysis implied that PSK significantly extended survival in ER-negative, Stage IIA patientswithout lymph node involvement (Toi et al., 1992).  However, in a further large trial, Morimoto et al. (1996) could find no statistical evidence of any benefit from PSK.

These contradictory studies may have been clarified by Yokoe et al. (1997) who compared HLA B40 antigen positive patients treated with PSK against B40 negatives.  It was found that B40-positive patients treated with PSK (3g/daily, two month course each year) in addition to chemotherapy had an improved 10 year overall survival rate compared to B-40 negative patients.  Thus, HLA B40 may be a predictive factor for PSK response.

The foregoing studies give strong indications of the potential benefits of incorporating PSK into some cancer treatments as an adjunct to radio- or chemotherapy.  Furthermore, PSK can improve immune status secondary to the side effects associated with traditional therapies.  As stated by Kidd (2000)  “after a quarter century of trials indicating PSK can improve cancer survival, the cumulative human findings amount to a recommendation for its inclusion in standard anticancer protocols. With its risk for adverse effects virtually nonexistent, PSK’s contribution to the benefit-risk profiles of these protocols can only be positive”.

Extracts taken from: THE ROLE OF POLYSACCHARIDES DERIVED FROM MEDICINAL MUSHROOMS IN CANCER (icnet.uk)

PSP and clinical trials

While PSK has been almost exclusively developed and tested within Japan, PSP in contrast is a product of China and continues to be assessed for efficacy safety by their scientists and oncologists.  There is a close similarity between PSK and PSP polypeptides although PSP lacks fucose and instead contains arabinose and rhamnose.  Since the first development of PSP in 1983 there has been rapid progress through human clinical trials.  Phase I clinical trials were carried out by Xu (1993) and it was shown that an oral dose of up to 6g/day was well talented and lacking in side-effects.  Patients showed improvement in appetite and general condition, together with a stabilisation of haematopoietic parameters.

The Phase II study by the Shanghai PSP Research Group with 8 hospitals in Shanghai was carried out using patients with cancers of the stomach, lung and oesophagus. The dosage was 1g three times daily to a total of 190g.  Results confirmed the role of PSP as a biological response modifer improving the immunological status of the patients after surgery, radiotherapy and/or chemotherapy (Liu and Zhou, 1993).  Following the success of the Phase II clinical trials, a Phase III trial was conducted in a large cohort of patients (650) in Shanghai hospitals.  189 were randomised to taking PSP and placebo;  461 patients were unblinded to their therapy (Liu et al., 1999).  These trials showed that PSP improved disease-free survival of gastric, oesophageal and non-small-cell lung cancers while again substantially reducing the normal unpleasant side-effects of conventional treatments (Sun and Zhu, 1999; Sun et al., 1999).  PSP had a protective effect on the immunological functions of conventionally-treated patients, thus demonstrating that PSP can be classified as a clinical biological response modifier.  Other BRMs such as LAK cells, IL-2, α y IFN or TNF are also being used in the treatment of advanced cancer cases (Liu, 1999).  Yet, these drugs at effective doses, in many cases, produce quite severe side-effects such as fevers, chills, rashes, arthralgia, hypotension, oliguria, pulmonary oedema, congestive heart failure and CNS toxicities.  Mao et al. (1998) have shown dramatic anti-tumour effects when PSP was combined with IL-2.  As side-effects of IL-2 are dosage and schedule dependent, it isreasonable to expect that with PSP, a lower dose of IL-2 could be used clinically withsubsequent decrease in the severity of the side-effects (McCune and Chang, 1993).

A further observation noted that PSP in combination with radiotherapy induced a significant increase in the percentage of apoptotic cells at 24h, compared with radiation alone, and it has been surmised that the antitumour mechanism of PSPaction may also involve the induction of DNA damage by apoptosis in the target cancer cells (Stephens et al., 1991). A common adverse reaction of radiotherapy and chemotherapy is haematopoietic toxicity.  Several studies have shown a strong amelioration of thesetoxic effects by PSP (Shiu et al., 1992; Sun et al., 1999).

In a double-blind Phase II trial in Shanghai hospitals almost 300 patients suffering from gastric, oesophageal or lung cancer  were treated with conventional radiotherapy and/or chemotherapy together with PSP or shark liver oil (batyl alcohol).  Quality of life was assessed by marked improvement of clinical symptoms as well as improvements in blood profiles and/or immune indices and significant improvement in Karnovsky performance status or body weight.   PSP improved overall clinical symptoms, together with most symptoms associated with cancer therapy.  PSP was found to be effective for 82% of the patients compared with 48%for batyl alcohol (Liu and Zhou, 1993).

Many Phase III clinical trials of PSP combined with conventional therapies have demonstrated significant benefits against cancers of the stomach, oesophagus and lung (Jong and Yang, 1999; Yang, 1999).  Most studies with PSP have not fullyexplored the long-term survival benefit although in an open-label, randomised trial in oesophageal cancer has shown that PSP did significantly improve one-year and three-year survival (Yao, 1999).  Liu (1999) has commented on the favourable action of PSP in patients receiving bone autologous marrow transplants.

The corpus of laboratory and clinical evidence that PSP offers considerable benefits to patients suffering from cancers of the stomach, oesophagus and lung have led to the Chinese Ministry of Public Health granting it a regulatory license.

Extracts taken from: THE ROLE OF POLYSACCHARIDES DERIVED FROM MEDICINAL MUSHROOMS IN CANCER (icnet.uk)

This extract taken from quantumhealing.co.za details various trials and treatments of Coriolus Veriscola.

It shrank his liver tumor by 90%––after his doctor gave up on him.

A man describes his oncologist as “the most negative man I ever met.” The doctor treated Mr. G. for liver cancer for six years, then gave him up as untreatable. “After the chemo failed, he threw up his hands, shrugged his shoulders, wished me good luck, and said there was nothing else he could do,” according to Mr. G. “And surgery couldn’t be performed either, because the consulting surgeon saw that the tumor was wrapped around my vena cava blood vessel.”

Mr G. told his oncologist, “I totally reject what you are telling me. I do not accept that nothing can be done to affect the outcome of this disease.” The doctor said, “Well, I know what I’m talking about when it comes to cancer. I’m a scientist.”

Mr G. shot back, “Yes, but you’re not God!” Four years later the patient was healthy again after using the type of therapies known as CAIM (complementary/ alternative/integrative medicine), especially including capsules containing the powdered extract of a mushroom, Coriolus versicolor. Mr G. learned about the remedy on the Internet and he can tell you all about it, having downloaded nearly 400 studies.

Amazingly, Mr. G.’s liver cancer reduced to less than ten percent of its original size. His CEA (carcinoembryonic antigen) cancer marker fell more than two-thirds from 296 to 97.9.

What is Coriolus Versicolor?

Like all mushrooms, Coriolus versicolor is a fungus, one of more than a half million varieties worldwide. Many of them have been known for thousands of years to have medicinal properties. And as you may know, gourmets the world over prize both wild and commercially grown mushrooms. Some European cookbooks even call them “flowers of the fall.” Whatever you call them, certain mushrooms are a perfect food for staying trim and healthy. They have little or no fat and some species, like Coriolusversicolor, boast valuable therapeutic and nutritional benefits. But a few fungi are poisonous and we do not recommend that nonexperts attempt to harvest their own. Coriolus versicolor goes by a number of botanical names, including Trametes versicolor and Boletus versicolor.

“Versicolor” refers to the mushroom’s various colors. In North America, the common name is “turkey tail,” while in Japan it is called by a name meaning “mushroom by the river bank” and in China its name indicates it’s a cloud fungus that grows best in the rain.

Over 400 clinical studies have shown that a purified extract derived from the mushroom Coriolus versicolor offers strong benefits for the immune system. Clinical studies indicate the extract’s ingredients are especially effective against stomach, uterine, colon and lung cancer.

Anecdotal evidence and clinical experience suggest it also works well against prostate, breast, liver and colorectal  cancer. Studies of rats and mice show that this mushroom is effective against many experimental animal cancers such as sarcoma and hepatoma.

Martha I.’s lung cancers disappear

“Of course,” says Dr. Bailey, “some cancer patients take Coriolus versicolor even while they engage in radiation treatment or chemotherapy. Or the patients don’t submit to chemotherapy or radiotherapy at all but rely, instead, exclusively on nutritional therapies with the medicinal mushroom as the main treatment ingredient.

“For example, one of my patients, Martha I., a 34-year-old woman working in the health field, consulted me with a cancer spreading at two sites in her lungs. Orthodox treatment had been tried but no longer was effective. She discontinued her smoking of two cigarette packs a day and embarked on nutritional therapies.

The nutrients included Martha’s completing six months of taking Coriolus versicolor. After this halfyear, radiological examination showed that all of her lung tumors had disappeared. Seeing her current progress, orthodox medicine probably would declare this patient to be cured.”

Blood tests show how the mushroom boosts immunity

I spoke with a doctor who measures natural killer cell (NK) counts and considers them a valuable cancer

marker. Kenneth Bock, M.D., is the medical director of two holistic medical clinics, one in Rhinebeck, New York and the other in Albany. “Because it increases natural killer (NK) cell activity, I think of using Coriolus versicolor mainly when I’m confronted with a patient suffering from cancer or a viral infection,” he says. “This mushroom is one of the main medicinal compounds I use to boost a diminished blood reading which records NK activity. The mushroom’s active biological response modifier produces a marked improvement in NK cell function and number, something I monitor by blood testing. If the blood reading is low, my patient takes greater amounts of PSK capsules. And, although it’s an expensive and sophisticated assay, I repeat my NK cell testing inside of a month or two. In a number of patients, I’ve seen some nice blood test improvement.”

Dr. Bock finds that a few patients with advanced metastatic cancer see their NK counts jump from 2 or 3 to a normal 20 to 50.

Patient’s immune system recovers

“I can illustrate what I’m saying by providing a before-and-after case history plus the literature that backs my claim,” Dr. Bock states. His patient was a white, married computer consultant named Marty E., sixty years old and suffering from high blood pressure and arteriosclerosis when he was also found to have polyps on his larynx. These were removed, with radiation therapy as a follow-up. But then Marty E. was also found to have prostate cancer.

“His blood test showed diminished natural killer cell activity at the level of 6 m/u,” Dr. Bock states. “Still, Marty wanted no conventional therapy for prostate cancer. So I started him on alternative medical therapies for prostate cancer and to improve his deficient NK cell activity. Coriolus versicolor was a definite part of his treatment regimen.

“Within two months, the patient’s NK cell activity elevated to 18 m/u. And two months after that his NK cell activity increased to a normal 31 m/u. Now the man is doing well physically, and he tells me he feels great! I would say this type of response to the  PSK therapy is usual; the patient’s quality of life does improve dramatically and he or she feels asense of well-being,” according to Dr. Bock.

A naturpathic doctor named Tori Hudson told of her clinical experience using PSK for breast cancer patients during and after chemotherapy. “My impression is that patients taking Coriolus versicolor are experiencing less side effects from chemotherapy such as diminished fatigue, less nausea (but not less hair loss), and more stable white blood cell counts. I have not measured natural killer cell counts,” she states.

Animal studies confirm what patients see for themselves

Animal studies show PSK is effective against a long list of cancers including melanoma, sarcoma, mammary cancer, colon cancer and lung cancer. Studies also show it inhibits metastasis to other sites. The studies indicate PSK enhances the immune system and battles cancer cells. It’s been shown to prolong the survival time and stimulate the production of cancer antibodies in mice with cancer.

PSK is also a potent antiviral remedy that may hold new hope for HIV-AIDS. It even lowers cholesterol in animals and speeds up recovery from burns in rabbits when used in combination with the herb Astragalus membranaceus.

Can be used in combination with conventional treatments

Human patients who have decided to stick with conventional chemotherapy and radiation therapy need to know that PSK renders these toxic treatments much more effective, as shown by a number of clinical studies.

A Japanese study looked at the effectiveness of 200 phytochemicals (plant substances) when used in combination with chemotherapy and radiation. Coriolus versicolor was found to be the best of the bunch. The researchers suggest that this medicinal mushroom seems to protect the immune system from being suppressed by prolonged use of chemotherapy drugsand by the cancer itself.

Further investigations indicate a marked improvement in the survival rates of chemo and radiationpatients taking the mushroom therapy when compared with those who did not. For patients with Stage I lung cancer observed over ten years, the tumor shrinkage and survival rate was 39 percent for those taking PSK compared to only 16 percent for patients receiving the toxic therapies without the mushroom extract. That’s a huge difference––more than twice as many survived and/or improved with the help of PSK.

Those lung cancer patients with more serious Stage II cancer experienced a 22 percent tumor shrinkage and survival rate over ten years when they took Coriolus versicolor orally while being treated with chemo or radiation. Among the people who didn’t take the herbal remedy the figure was a mere five percent.

From this study of 185 lung cancer patients it appears the mushroom extract can make the toxic therapies anywhere from two to four times more effective.

A Japanese study of 262 gastric cancer patients tested the mushroom’s efficacy following surgery. During a follow-up period ranging from five to seven years, the half who received the mushroom extract survived at substantially higher rates. The researchers concluded that PSK was a useful adjunctive therapy to surgery and chemo.

A Japanese study of breast cancer patients found similar results: Those who received PSK along with chemotherapy had better outcomes than those who did not. And a study of 28 patients suffering from acute leukemia––all on chemotherapy––showed an average survival time of 21 months for those who took the mushroom extract and 12 months for those who did not.

When researching the production and manufacture of electronic cigarettes and their refills the most important factor to consider is the reliability of the manufacture and verification of the refill ingredients. The reason that this is so important lies in the fact that the materials used in the refills bring with them a whole new set of issues as deadly as the tobacco that we as smokers are trying to avoid.

It is hardly worth getting yourself off of tobacco if you are going to jump out of the frying pan into the fire!

The main ingredients in an electronic cigarette refill are propylene glycol, glycerol, nicotine, water and a flavoring.

I am sure most readers will jump at the nicotine as being the potential toxin in this list, but in fact the reasons behind the need for safety is the propylene glycol.

There are two reasons why propylene glycol can become an issue.

1. The first is that there are two types of propylene glycol, industrial grade and pharmaceutical grade. Industrial grade is more concentrated and is a deadly toxin and not fit for consumption. Pharmaceutical grade propylene glycol is a much more diluted form and is used in many foods. As you would expect, pharmaceutical grade is a more expensive chemical process.

2. The second reason for the need for care is a close neighbor to propylene glycol, Diethylene glycol or DEG. DEG is found in antifreeze and is so close to acting in the same manner as propylene glycol that some anti-freezes have substituted industrial grade PG for DEG because whilst still toxic, industrial grade PG is less toxic than DEG.

Now I can hear you say….they wouldnt use the toxic stuff in a consumable product….

Well, when costs are involved in a highly competitive market that has no regulation..who knows. DEG caused 80+ deaths in Nigeria in 2006 when it was substituted for PG in a tooth product and a Chinese hospital was sued for using DEG. The FDA also found DEG in a sample of electronic cigarette refills from a US supplier import batch.

With Chinas track record in cost cutting and poor regulation….we all remember the lead in the paint and plastic in the milk!, then knowing that your refills contain what they are supposed to is an important issue most people have overlooked in this new industry.

To avoid confusion…inLife is the only company that provides electronic cigarettes manufactured in an FDA registered laboratory. This means that the ingredients are independently verified and are what the label says they are.

Electronic cigarettes are the single greatest new technology to affect public health since inoculation. Lets not spoil the party for a ‘hapeth of tart’